Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,237 across all filing types
Latest filing 2025-07-22 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled for July 29, 2025. The purpose of the meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The letter also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document is short (1900 characters) and serves as an announcement of a future event (board meeting and financial results approval), not the financial results report itself. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain actual financial data or detailed report content.
2025-07-22 English
Copy of Newspaper Publication
Regulatory Filings
2025-07-10 English
Please find enclosed herewith Newspaper Advertisement of Notice of 40th Annual General Meeting, e-voting and Book Closure Information.
Regulatory Filings
2025-07-10 English
Please find enclosed herewith the Business Responsibility and Sustainability Report for the FY 2024-2025.
Environmental & Social Information Classification · 100% confidence The document is titled 'Business Responsibility and Sustainability Report for the Financial Year 2024-2025' and is submitted pursuant to SEBI regulations. It explicitly states that it forms an integral part of the Annual Report for FY 2024-25. The content includes detailed disclosures on environmental, social, governance, and sustainability matters, employee data, CSR details, and risk management related to responsible business conduct. There are no financial statements or earnings data presented, but rather a focus on ESG and sustainability reporting. This matches the definition of an Environmental & Social Information report (ESG report). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is Environmental & Social Information (SR).
2025-07-09 English
Updates
Environmental & Social Information Classification · 95% confidence The document is titled 'Business Responsibility and Sustainability Report for the Financial Year 2024-2025' and is described as forming an integral part of the Annual Report for the financial year 2024-2025. The content includes detailed disclosures on environmental, social, and governance (ESG) factors such as employee demographics, CSR details, grievance redressal, and material responsible business conduct issues. There is no indication that this is a full Annual Report (10-K) or an earnings release, but rather a focused report on sustainability and business responsibility. This matches the definition of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is SR with high confidence.
2025-07-09 English
Please find enclosed herewith the Notice of the 40th AGM of Bliss GVS Pharma Limited ("the Company") scheduled to be held on Thursday, July 31, 2025, at 11:30 A.M. (IST) through VC/OAVM. ....
AGM Information Classification · 100% confidence The document is a detailed notice of the 40th Annual General Meeting (AGM) of Bliss GVS Pharma Limited, including the agenda items such as adoption of financial statements, declaration of dividend, re-appointment of directors, and appointment of secretarial auditors. It references the Annual Report for the financial year 2024-2025 but does not contain the full report itself. The document is lengthy (15,000 characters) and includes regulatory references to SEBI and MCA circulars, meeting logistics, and voting procedures. It is clearly a notice and related materials for the AGM, not the Annual Report or any other financial report. Therefore, the appropriate classification is AGM Information (AGM-R).
2025-07-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.